Volume 3.27 | Jul 14

Mammary Cell News 3.27, July 14, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Cell Therapy News on Facebook  Mammary Cell News on Twitter
A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer
Scientists demonstrate the fundamental role of the prolyl isomerase Pin1 in mutant p53 oncogenic functions. [Cancer Cell]


Study Finds New Points of Attack on Breast Cancers Not Fueled by Estrogen
Scientists provide the first details of the cancer cell machinery that carries out the hormone’s relentless growth orders. [Press release from Dana-Farber Cancer Institute discussing online prepublication in Cancer Cell]

Targeted Agent Addition to Herceptin Has Positive Effect on Metastatic HER-2 Breast Cancer
Adding Afinitor® to Herceptin®, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in the Journal of Clinical Oncology]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Selective Killing of Cancer Cells by a Small Molecule Targeting the Stress Response to Reactive Oxygen Species
Scientists used a cell-based small-molecule screening and quantitative proteomics approach that resulted in the unbiased identification of a small molecule that selectively kills cancer cells but not normal cells. [Nature]

Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
Through analysis of the androgen receptor (AR) cistrome and androgen-regulated gene expression in estrogen receptor negative/HER2 positive breast cancers researchers found that AR mediates ligand-dependent activation of Wnt and HER2 signaling pathways through direct transcriptional induction of WNT7B and HER3. [Cancer Cell]

Engagement of I-Branching β-1, 6-N-Acetylglucosaminyltransferase 2 in Breast Cancer Metastasis and TGF-β Signaling
In this study, investigators have showed that GCNT2, a gene-encoding glucosaminyl (N-acetyl) transferase 2, I-branching enzyme, is overexpressed in highly metastatic breast cancer cell lines of human and mouse origin and basal-like breast tumor samples. [Cancer Res]

p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage
In this study, scientists investigated the mechanisms of p53-dependent BRCA1 subcellular distribution and DNA damage-induced nuclear export, as well as the impact on the resulting cytotoxic response to therapy in human breast cancer. [Cancer Res]

Overexpression of 14-3-3ζ in Cancer Cells Activates PI3K via Binding the p85 Regulatory Subunit
Researchers investigated the clinical relevance and molecular mechanism of 14-3-3ζ-overexpression-mediated Akt phosphorylation, and its potential impact on breast cancer progression. [Oncogene]

Hypoxia Inducible Factor-1 Is Activated by Dysregulated Cyclin E During Mammary Epithelial Morphogenesis
Investigators have studied dysregulated cyclin E in epithelial tissues using organotypic cultures of human mammary epithelial cells and a murine model. [Mol Cell Biol]

Comparative Gene Expression Analysis in Mouse Models for Identifying Critical Pathways in Mammary Gland Development
In this article, scientists applied a standardized microarray preprocessing to four independent studies, and then used gene set enrichment analysis to identify the key pathways. [Breast Cancer Res Treat]


Increased Risk of Locoregional Recurrence for Women with T1-2N0 Triple-Negative Breast Cancer Treated with Modified Radical Mastectomy without Adjuvant Radiation Therapy Compared with Breast-Conserving Therapy
The purpose of this study is to evaluate the risk of locoregional recurrence associated with locoregional treatment of women with primary breast cancer tumors negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (triple-negative breast cancer). [J Clin Oncol]

Phase I/II Study of Trastuzumab in Combination with Everolimus (RAD001) in Patients with HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
The trial evaluated the safety and efficacy of the combination of everolimus and trastuzumab in women with HER2-overexpressing metastatic breast cancer that progressed on trastuzumab-based therapy. [J Clin Oncol]

Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer
The purpose of this study is to determine, by molecular imaging, how in vivo pharmacodynamics of estrogen-estrogen receptor binding differ between types of standard endocrine therapy. [Clin Cancer Res]

Functional Polymorphisms in UDP-Glucuronosyltransferases and Recurrence in Tamoxifen-Treated Breast Cancer Survivors
Investigators measured the association between functional polymorphisms in key UDP-glucuronosyltransferases (UGT2B15*2, UGT2B7*2, and UGT1A8*3) and the recurrence rate among breast cancer survivors. [Cancer Epidemiol Biomarkers Prev]


Sunshine Biopharma’s Adva-27a Is 16-Times More Effective at Killing Multidrug Resistant Breast Cancer Cells
Sunshine Biopharma Inc. announced that it has completed a detailed cytotoxicity study of its lead compound, Adva-27a, in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line. [Sunshine Biopharma Press Release]

Nuvilex Announces Successful Breast Cancer Preclinical Studies
In recently completed work using the Nuvilex live–cell encapsulation technology and a combination of two anticancer drugs, clear positive results of elimination of breast tumors were achieved in preclinical models. [Nuvilex, Inc. Press Release]

Atossa Genetics Acquires Rights to Patents Covering a Novel Screening Test for Breast Cancer from the Dr. Susan Love Research Foundation
Atossa Genetics, Inc. announced that it has acquired all of the ownership rights to U.S. patent 7,879,614, issued February 1, 2011, and pending U.S. application 11/958,597, filed January 31, 2011, from the Dr. Susan Love Research Foundation. [Atossa Genetics, Inc. Press Release]

RXi Pharmaceuticals Strengthens NeuVax™ (E75) Patent Portfolio
RXi Pharmaceuticals Corporation announced that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax™ (E75). [RXi Pharmaceuticals Corporation Press Release]


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Cancer Research Global Summit
August 16-17, 2011
London, United Kingdom

Visit our events page to see a complete list of events in the mammary cell community.


Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Postdoctoral Fellow (Indiana University School of Medicine-South Bend)

Postdoctoral Position (Tufts Medical Center)

Postdoctoral Fellow (Roswell Park Cancer Institute)

Laboratory Project Scientist (University of California, San Diego)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us